CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation

B. Wagner, K. Dahse, B. Zimmermann, C. R. Meier, H. Rasche

Research output: Contribution to journalArticle

Abstract

Purpose: Haematopoietic, especially platelet recovery is crucial in autologous stem cell rescue after high dose therapy (HDTR) in cancer. We were interested in the dose-effect-relationship between the haematopoietic progenitor cells (routinely quantified as CD34+ cells and CFU-GM) applied for transplantation and the duration of transfusion dependence (red cells and platelets). Methods: Haematopoietic progenitors in stem cell transplantais were determined by routine methods: CD34+ cells were quantified by flow cytometry, CFU-GM by cell culture in semi-solid medium containing methylcellulose. HDTR was performed in 21 patients of whom 7 received a tandem regimen. Results: After autologous stem cell reinfusion (n=28) of in the median 3.1 × 10E6 CD34+ cells/kg body weight (BW) (range: 2.0-7.9 × 10E6 CD34+ cells/kgBW) and 8.3 (3.5-19.1) × 10E5 CFU-GM/kg BW patients required 2 (0-8) red cell concentrates and 4 (1-10) platelet transfusions. Neutropenia (<500/×l) recovered within 9 (8-11) days after transplantation. Platelet dependence lasted 9.5 (5-15) days. The doses (CD34+ and CFU-GM, resp.) applied did neither correlate with the duration of neutropenia nor the interval of platelet dependence. In 4 patients the latter was beyond the upper quartile inspite of rapid recovery of granulocytopoiesis. Patients required substitution of red cells for 7.5 (0-18) days. Surprisingly, this Intervall was inversely correlated with the stem cell doses applied while the correlation was better with the amounts of CD34+ cells (r= - 0.703, p< 0.01) than those of CFU-GM (r= - 0.483, p= 0.01). These preliminary findings need to be confirmed in further studies. Conclusion: We like others did not find a correlation between platelet recovery and "stem cell dose" as assessed by CD34+ and CFU-GM. Additional parameters such as megacaryocyte progenitors are needed to ameliorate therapy safety and shorten hospitalization.

Original languageEnglish (US)
Pages (from-to)54
Number of pages1
JournalInfusionstherapie und Transfusionsmedizin
Volume26
Issue numberSUPPL. 1
StatePublished - 1999
Externally publishedYes

Fingerprint

cell transplantation
Granulocyte-Macrophage Progenitor Cells
Stem Cell Transplantation
blood cells
stem cells
Blood Cells
Blood Platelets
Stem Cells
dosage
cells
neutropenia
Neutropenia
therapeutics
Transplantation
Body Weight
Platelet Transfusion
Methylcellulose
methylcellulose
duration
body weight

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Food Science

Cite this

Wagner, B., Dahse, K., Zimmermann, B., Meier, C. R., & Rasche, H. (1999). CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation. Infusionstherapie und Transfusionsmedizin, 26(SUPPL. 1), 54.

CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation. / Wagner, B.; Dahse, K.; Zimmermann, B.; Meier, C. R.; Rasche, H.

In: Infusionstherapie und Transfusionsmedizin, Vol. 26, No. SUPPL. 1, 1999, p. 54.

Research output: Contribution to journalArticle

Wagner, B, Dahse, K, Zimmermann, B, Meier, CR & Rasche, H 1999, 'CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation', Infusionstherapie und Transfusionsmedizin, vol. 26, no. SUPPL. 1, pp. 54.
Wagner, B. ; Dahse, K. ; Zimmermann, B. ; Meier, C. R. ; Rasche, H. / CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation. In: Infusionstherapie und Transfusionsmedizin. 1999 ; Vol. 26, No. SUPPL. 1. pp. 54.
@article{f6ce953d97104e91bb93c7884f2d4214,
title = "CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation",
abstract = "Purpose: Haematopoietic, especially platelet recovery is crucial in autologous stem cell rescue after high dose therapy (HDTR) in cancer. We were interested in the dose-effect-relationship between the haematopoietic progenitor cells (routinely quantified as CD34+ cells and CFU-GM) applied for transplantation and the duration of transfusion dependence (red cells and platelets). Methods: Haematopoietic progenitors in stem cell transplantais were determined by routine methods: CD34+ cells were quantified by flow cytometry, CFU-GM by cell culture in semi-solid medium containing methylcellulose. HDTR was performed in 21 patients of whom 7 received a tandem regimen. Results: After autologous stem cell reinfusion (n=28) of in the median 3.1 × 10E6 CD34+ cells/kg body weight (BW) (range: 2.0-7.9 × 10E6 CD34+ cells/kgBW) and 8.3 (3.5-19.1) × 10E5 CFU-GM/kg BW patients required 2 (0-8) red cell concentrates and 4 (1-10) platelet transfusions. Neutropenia (<500/×l) recovered within 9 (8-11) days after transplantation. Platelet dependence lasted 9.5 (5-15) days. The doses (CD34+ and CFU-GM, resp.) applied did neither correlate with the duration of neutropenia nor the interval of platelet dependence. In 4 patients the latter was beyond the upper quartile inspite of rapid recovery of granulocytopoiesis. Patients required substitution of red cells for 7.5 (0-18) days. Surprisingly, this Intervall was inversely correlated with the stem cell doses applied while the correlation was better with the amounts of CD34+ cells (r= - 0.703, p< 0.01) than those of CFU-GM (r= - 0.483, p= 0.01). These preliminary findings need to be confirmed in further studies. Conclusion: We like others did not find a correlation between platelet recovery and {"}stem cell dose{"} as assessed by CD34+ and CFU-GM. Additional parameters such as megacaryocyte progenitors are needed to ameliorate therapy safety and shorten hospitalization.",
author = "B. Wagner and K. Dahse and B. Zimmermann and Meier, {C. R.} and H. Rasche",
year = "1999",
language = "English (US)",
volume = "26",
pages = "54",
journal = "Transfusion Medicine and Hemotherapy",
issn = "1660-3796",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - CD34+ and CFU-GM doses don't predict platelet recovery in autologous blood stem cell transplantation

AU - Wagner, B.

AU - Dahse, K.

AU - Zimmermann, B.

AU - Meier, C. R.

AU - Rasche, H.

PY - 1999

Y1 - 1999

N2 - Purpose: Haematopoietic, especially platelet recovery is crucial in autologous stem cell rescue after high dose therapy (HDTR) in cancer. We were interested in the dose-effect-relationship between the haematopoietic progenitor cells (routinely quantified as CD34+ cells and CFU-GM) applied for transplantation and the duration of transfusion dependence (red cells and platelets). Methods: Haematopoietic progenitors in stem cell transplantais were determined by routine methods: CD34+ cells were quantified by flow cytometry, CFU-GM by cell culture in semi-solid medium containing methylcellulose. HDTR was performed in 21 patients of whom 7 received a tandem regimen. Results: After autologous stem cell reinfusion (n=28) of in the median 3.1 × 10E6 CD34+ cells/kg body weight (BW) (range: 2.0-7.9 × 10E6 CD34+ cells/kgBW) and 8.3 (3.5-19.1) × 10E5 CFU-GM/kg BW patients required 2 (0-8) red cell concentrates and 4 (1-10) platelet transfusions. Neutropenia (<500/×l) recovered within 9 (8-11) days after transplantation. Platelet dependence lasted 9.5 (5-15) days. The doses (CD34+ and CFU-GM, resp.) applied did neither correlate with the duration of neutropenia nor the interval of platelet dependence. In 4 patients the latter was beyond the upper quartile inspite of rapid recovery of granulocytopoiesis. Patients required substitution of red cells for 7.5 (0-18) days. Surprisingly, this Intervall was inversely correlated with the stem cell doses applied while the correlation was better with the amounts of CD34+ cells (r= - 0.703, p< 0.01) than those of CFU-GM (r= - 0.483, p= 0.01). These preliminary findings need to be confirmed in further studies. Conclusion: We like others did not find a correlation between platelet recovery and "stem cell dose" as assessed by CD34+ and CFU-GM. Additional parameters such as megacaryocyte progenitors are needed to ameliorate therapy safety and shorten hospitalization.

AB - Purpose: Haematopoietic, especially platelet recovery is crucial in autologous stem cell rescue after high dose therapy (HDTR) in cancer. We were interested in the dose-effect-relationship between the haematopoietic progenitor cells (routinely quantified as CD34+ cells and CFU-GM) applied for transplantation and the duration of transfusion dependence (red cells and platelets). Methods: Haematopoietic progenitors in stem cell transplantais were determined by routine methods: CD34+ cells were quantified by flow cytometry, CFU-GM by cell culture in semi-solid medium containing methylcellulose. HDTR was performed in 21 patients of whom 7 received a tandem regimen. Results: After autologous stem cell reinfusion (n=28) of in the median 3.1 × 10E6 CD34+ cells/kg body weight (BW) (range: 2.0-7.9 × 10E6 CD34+ cells/kgBW) and 8.3 (3.5-19.1) × 10E5 CFU-GM/kg BW patients required 2 (0-8) red cell concentrates and 4 (1-10) platelet transfusions. Neutropenia (<500/×l) recovered within 9 (8-11) days after transplantation. Platelet dependence lasted 9.5 (5-15) days. The doses (CD34+ and CFU-GM, resp.) applied did neither correlate with the duration of neutropenia nor the interval of platelet dependence. In 4 patients the latter was beyond the upper quartile inspite of rapid recovery of granulocytopoiesis. Patients required substitution of red cells for 7.5 (0-18) days. Surprisingly, this Intervall was inversely correlated with the stem cell doses applied while the correlation was better with the amounts of CD34+ cells (r= - 0.703, p< 0.01) than those of CFU-GM (r= - 0.483, p= 0.01). These preliminary findings need to be confirmed in further studies. Conclusion: We like others did not find a correlation between platelet recovery and "stem cell dose" as assessed by CD34+ and CFU-GM. Additional parameters such as megacaryocyte progenitors are needed to ameliorate therapy safety and shorten hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=33749392933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749392933&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749392933

VL - 26

SP - 54

JO - Transfusion Medicine and Hemotherapy

JF - Transfusion Medicine and Hemotherapy

SN - 1660-3796

IS - SUPPL. 1

ER -